Federal Register / Vol. 69, No. 226 / Wednesday, November 24, 2004 / Rules and Regulations 68251

Authority: 12 U.S.C. 1462, 1462a, 1463, 

1464, 1467a, 1828, 2901.

■ 40. In § 575.13, revise paragraphs (c)(3) 

and (f), and delete paragraphs (c)(4) and 

(g) to read as follows:

§ 575.13 Procedural requirements.

* * * * *

(c) * * *

(3) Public notice, public comment, 

and meetings. This part imposes no 

requirements regarding public notice, 

public comment, or meetings for mutual 

holding company reorganizations. 

However, mutual holding company 

reorganizations under this part are 

subject to applicable public notice, 

public comment, and meeting 

requirements under the Bank Merger 

Act regulations at § 563.22(e)(1) of this 

chapter and the Savings and Loan 

Holding Company Act regulations at 

§ 574.6(d) and (e) of this chapter.

* * * * *

(f) Disclosure. The rules governing 

disclosure of any notice or application 

submitted pursuant to this part, or any 

public comment submitted pursuant to 

paragraph (c) of this section, shall be the 

same as set forth in § 574.6(f) of this 

chapter for notices, applications, and 

public comments filed under part 574 of 

this chapter.

* * * * *

Dated: November 18, 2004. 

By the Office of Thrift Supervision. 

James E. Gilleran, 

Director.

[FR Doc. 04–26010 Filed 11–23–04; 8:45 am] 

BILLING CODE 6720–01–P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration 

14 CFR Part 39 

[Docket No. 2003–NE–51–AD; Amendment 

39–13881; AD 2004–24–05] 

RIN 2120–AA64 

Airworthiness Directives; Rolls-Royce 

Deutschland Ltd. & Co KG (formerly 

Rolls-Royce plc), Models Spey 555–15, 

555–15H, 555–15N, and 555–15P 

Turbojet Engines

AGENCY: Federal Aviation 

Administration (FAA), DOT.

ACTION: Final rule.

SUMMARY: The FAA is adopting a new 

airworthiness directive (AD) for RollsRoyce Deutschland Ltd. & Co KG (RRD) 

(formerly Rolls-Royce plc), models Spey 

555–15, 555–15H, 555–15N, and 555–

15P turbojet engines, with magnesium 

split low pressure (LP) compressor case, 

part number (P/N) EU.73418A installed. 

This AD requires replacement of the 

magnesium split LP compressor case 

with a serviceable compressor case that 

is a combination of a steel front LP 

compressor case and a shortened split 

compressor case. This AD results from 

several reports of bird ingestion and LP 

compressor stage 1 rotor blade failures 

that have resulted in penetration of the 

magnesium LP compressor case, and 

damage to the airplane.

DATES: This AD becomes effective 

December 29, 2004.

ADDRESSES: You can get the service 

information identified in this AD from 

Rolls-Royce Deutschland Ltd & Co KG, 

Eschenweg 11, D–15827 Dahlewitz, 

Germany, telephone +49 (0) 33–7086–

1768; fax +49 (0) 33–7086–3356. 

You may examine the AD docket at 

the FAA, New England Region, Office of 

the Regional Counsel, 12 New England 

Executive Park, Burlington, MA.

FOR FURTHER INFORMATION CONTACT:

Jason Yang, Aerospace Engineer, Engine 

Certification Office, FAA, Engine and 

Propeller Directorate, 12 New England 

Executive Park, Burlington, MA 01803–

5299; telephone (781) 238–7747; fax 

(781) 238–7199.

SUPPLEMENTARY INFORMATION: The FAA 

proposed to amend 14 CFR part 39 with 

a proposed AD. The proposed AD 

applies to RRD models Spey 555–15, 

555–15H, 555–15N, and 555–15P 

turbojet engines, with magnesium split 

LP compressor case, P/N EU.73418A 

installed. We published the proposed 

AD in the Federal Register on February 

20, 2003 (68 FR 8157). That action 

proposed to require replacement of the 

magnesium split LP compressor case 

with a serviceable LP compressor case 

that is a combination of a steel front LP 

compressor case and a shortened split 

LP compressor case. 

Examining the AD Docket 

You may examine the AD Docket 

(including any comments and service 

information), by appointment, between 

8 a.m. and 4:30 p.m., Monday through 

Friday, except Federal holidays. See 

ADDRESSES for the location. 

Comments 

We provided the public the 

opportunity to participate in the 

development of this AD. We have 

considered the one comment received. 

One commenter requests that special 

flight permits be added to the final rule. 

We do not agree. On July 22, 2002, the 

FAA revised 14 CFR part 39 by adding 

the Special Flight Permit provision. 

Doing this allowed us to omit that 

provision from ADs, to help place the 

focus of ADs on the unsafe condition 

that created the need for each directive. 

ADs that allow Special Flight Permits 

with conditions, or that prohibit Special 

Flight Permits, will state those 

conditions in the compliance section. 

ADs that do not specify special flight 

conditions or do not prohibit special 

flight permits will not reference Special 

Flight Permits. If operators want to 

request Special Flight Permits, they 

must request them by following the 

procedure in 14 CFR part 39, § 39.25. 

Also, because this final rule requires 

that the actions be done within 60 

months after the effective date of the 

AD, we anticipate no requests for a 

Special Flight Permit due to the amount 

of lead time available to comply with 

the AD. 

Conclusion 

We have carefully reviewed the 

available data, including the comments 

received, and determined that air safety 

and the public interest require adopting 

the AD as proposed. 

Costs of Compliance 

There are about 184 RRD models Spey 

555–15, 555–15H, 555–15N, and 555–

15P turbojet engines of the affected 

design in the worldwide fleet. We 

estimate that 34 engines installed on 

airplanes of U.S. registry will be affected 

by this AD. We also estimate that it will 

take about 6 work hours per engine to 

perform the actions, and that the 

average labor rate is $65 per work hour. 

Required parts will cost about $37,000 

per engine. Based on these figures, we 

estimate the total cost of the AD to U.S. 

operators to be $1,271,260. 

Regulatory Findings 

We have determined that this AD will 

not have federalism implications under 

Executive Order 13132. This AD will 

not have a substantial direct effect on 

the States, on the relationship between 

the national government and the States, 

or on the distribution of power and 

responsibilities among the various 

levels of government. 

For the reasons discussed above, I 

certify that this AD: 

(1) Is not a ‘‘significant regulatory 

action’’ under Executive Order 12866; 

(2) Is not a ‘‘significant rule’’ under 

DOT Regulatory Policies and Procedures 

(44 FR 11034, February 26, 1979); and 

(3) Will not have a significant 

economic impact, positive or negative, 

on a substantial number of small entities 

under the criteria of the Regulatory 

Flexibility Act. 

We prepared a summary of the costs 

to comply with this AD and placed it in 

68252 Federal Register / Vol. 69, No. 226 / Wednesday, November 24, 2004 / Rules and Regulations 

the AD Docket. You may get a copy of 

this summary by sending a request to us 

at the address listed under ADDRESSES. 

Include ‘‘AD Docket No. 2003–NE–51–

AD’’ in your request.

List of Subjects in 14 CFR Part 39 

Air transportation, Aircraft, Aviation 

safety, Safety.

Adoption of the Amendment

■ Accordingly, under the authority 

delegated to me by the Administrator, 

the Federal Aviation Administration 

amends 14 CFR part 39 as follows:

PART 39—AIRWORTHINESS 

DIRECTIVES

■ 1. The authority citation for part 39 

continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

■ 2. The FAA amends § 39.13 by adding 

the following new airworthiness 

directive:

2004–24–05 Rolls-Royce Deutschland Ltd. 

& Co KG (formerly Rolls-Royce plc):

Amendment 39–13881. Docket No. 

2003–NE–51–AD. 

Effective Date 

(a) This airworthiness directive (AD) 

becomes effective December 29, 2004. 

Affected ADs 

(b) None. 

Applicability 

(c) This AD applies to Rolls-Royce 

Deutschland Ltd. & Co KG (RRD) (formerly 

Rolls-Royce plc), models Spey 555–15, 555–

15H, 555–15N, and 555–15P turbojet engines, 

with magnesium split low pressure (LP) 

compressor case, part number (P/N) 

EU.73418A installed. These engines are 

installed on, but not limited to, Fokker F.28 

Mark 1000, Mark 2000, Mark 3000, and Mark 

4000 series airplanes. 

Unsafe Condition 

(d) This AD is prompted by several reports 

of bird ingestion and LP compressor stage 1 

rotor blade failures that have resulted in 

penetration of the magnesium split LP 

compressor case and damage to the airplane. 

We are issuing this AD to prevent possible 

uncontained LP compressor stage 1 rotor 

blade failures that could result in damage to 

the airplane. 

Compliance 

(e) You are responsible for having the 

actions required by this AD performed within 

60 months after the effective date of this AD, 

unless the actions have already been done. 

Replacement of Magnesium Split LP 

Compressor Case With a Serviceable 

Compressor Case 

(f) Remove the magnesium split LP 

compressor case, P/N EU.73418A, from the 

engine and install a serviceable LP 

compressor case. Information on removing 

and replacing this P/N case can be found in 

RRD Service Bulletin No. Sp72–893, Revision 

3, dated August 25, 2003. 

Alternative Methods of Compliance 

(g) The Manager, Engine Certification 

Office, has the authority to approve 

alternative methods of compliance for this 

AD if requested using the procedures found 

in 14 CFR 39.19. 

Material Incorporated by Reference 

(h) None. 

Related Information 

(i) LBA airworthiness directive 2003–261, 

dated August 25, 2003, also addresses the 

subject of this AD.

Issued in Burlington, Massachusetts, on 

November 15, 2004. 

Jay J. Pardee, 

Manager, Engine and Propeller Directorate, 

Aircraft Certification Service.

[FR Doc. 04–25790 Filed 11–23–04; 8:45 am] 

BILLING CODE 4910–13–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES

Food and Drug Administration

21 CFR Part 522

Implantation or Injectable Dosage 

Form New Animal Drugs; Estradiol 

Benzoate and Testosterone Propionate

AGENCY: Food and Drug Administration, 

HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug 

Administration (FDA) is amending the 

animal drug regulations to reflect 

approval of supplemental new animal 

drug applications (NADAs) filed by Fort 

Dodge Animal Health, Division of 

Wyeth, and Ivy Laboratories, Division of 

Ivy Animal Health, Inc. The 

supplemental NADAs provide for the 

addition of statements to labeling of 

subcutaneous implants containing 

estradiol benzoate and testosterone 

propionate warning against the use of 

these products in calves to be processed 

for veal.

DATES: This rule is effective November 

24, 2004.

FOR FURTHER INFORMATION CONTACT: Eric 

S. Dubbin, Center for Veterinary 

Medicine (HFV–126), Food and Drug 

Administration, 7500 Standish Pl., 

Rockville, MD 20855, 301–827–0232, email: edubbin@cvm.fda.gov.

SUPPLEMENTARY INFORMATION: Fort 

Dodge Animal Health, Division of 

Wyeth, 800 Fifth St. NW., Fort Dodge, 

IA 50501, filed a supplement to NADA 

011–427 for SYNOVEX H (estradiol 

benzoate and testosterone propionate). 

Ivy Laboratories, Division of Ivy Animal 

Health, Inc., 8857 Bond St., Overland 

Park, KS 66214, filed a supplement to 

NADA 135–906 for COMPONENT E–H 

(estradiol benzoate and testosterone 

propionate) and COMPONENT E–H 

with TYLAN (estradiol benzoate and 

testosterone propionate with tylosin 

tartrate). The supplemental NADAs 

provide for the addition of statements to 

labeling warning against the use of these 

products in calves to be processed for 

veal. The supplemental applications are 

approved as of October 18, 2004, and 

the regulations are amended in 21 CFR 

522.842 to reflect the approvals and a 

current format. The basis of approval is 

discussed in the freedom of information 

summaries.

In accordance with the freedom of 

information provisions of 21 CFR part 

20 and 21 CFR 514.11(e)(2)(ii), 

summaries of safety and effectiveness 

data and information submitted to 

support approval of these applications 

may be seen in the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852, between 9 

a.m. and 4 p.m., Monday through 

Friday.

The agency has determined under 21 

CFR 25.33(a)(1) that these actions are of 

a type that do not individually or 

cumulatively have a significant effect on 

the human environment. Therefore, 

neither an environmental assessment 

nor an environmental impact statement 

is required.

This rule does not meet the definition 

of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because 

it is a rule of ‘‘particular applicability.’’

Therefore, it is not subject to the 

congressional review requirements in 5 

U.S.C. 801–808.

List of Subjects in 21 CFR Part 522

Animal drugs.

■ Therefore, under the Federal Food, 

Drug, and Cosmetic Act and under the 

authority delegated to the Commissioner 

of Food and Drugs and redelegated to the 

Center for Veterinary Medicine, 21 CFR 

part 522 is amended as follows:

PART 522—IMPLANTATION OR 

INJECTABLE DOSAGE FORM NEW 

ANIMAL DRUGS

■ 1. The authority citation for 21 CFR 

part 522 continues to read as follows:

Authority: 21 U.S.C. 360b.

■ 2. Section 522.842 is revised to read as 

follows: